160 Health International Limited Achieves Breakthrough in Digital Healthcare Collaboration with Over 720% Growth in 2025

Key Highlights

• Significant Expansion in 2025: 160 Health International Limited (“the Company” or “the Group”) announced a remarkable expansion in its digital healthcare and wellness solutions business, particularly through its core product, the “160AI Hospital” operational collaboration model.
• Major Collaboration Milestone: As of December 31, 2025, the Group entered into operational collaborations with 82 public hospitals of Class IIA or above, representing a year-on-year increase of more than 720% compared to 2024.
• Accelerated Growth in Q4: In the fourth quarter of 2025 alone, 52 new public hospitals joined the collaboration program, reflecting an extraordinary quarter-on-quarter growth of 420%.
• Innovative Business Model: All new collaborations were established under the Group’s innovative “160AI Hospital” operational collaboration business model, a core offering in its digital healthcare and wellness solutions portfolio.
• Market Penetration: This rapid expansion marks a pivotal step in the market penetration of the “160AI Hospital” model, now reaching a wider range of the healthcare system.

Details and Implications for Investors

The Board of Directors highlighted that this surge in business collaborations demonstrates the Group’s successful execution in expanding its footprint within the digital healthcare sector. The substantial increase in partnered hospitals—especially those of Class IIA or above—indicates strong market demand and acceptance of the “160AI Hospital” model, which could position the Company as a leader in digital healthcare integration across public hospitals.

The fourth quarter of 2025 alone contributed the majority of new partnerships, showcasing not only the scalability of the business model but also the Company’s ability to accelerate growth within a short period. This momentum suggests that the Group’s strategy and solutions are resonating well with key stakeholders in the healthcare industry.

Material Information for Shareholders

• Potential Impact on Share Price: The announcement of a 720% year-on-year increase in hospital collaborations and a 420% quarter-on-quarter growth in Q4 2025 is material information that could positively influence market perceptions and the Company’s share price. Such rapid expansion, especially with reputable Class IIA or above public hospitals, signals strong business performance in a key segment.
• Not a Profit Forecast: The Board emphasized that while the announcement reflects major progress in a specific business segment, it does not constitute a profit forecast or an explicit indication of the Company’s overall profitability for the year 2025. The overall results are still being finalized and are subject to various uncertainties, including market conditions and industrial policies.
• Preliminary Data Warning: The figures disclosed are based on preliminary assessments, have not been audited, and have not been reviewed by the audit committee. Investors should note that the Company may ultimately report either a profit or a loss for the year ended December 31, 2025. Final audited results will be disclosed in the Company’s upcoming annual report.
• Investor Caution: Shareholders and prospective investors are advised to exercise caution when dealing in the shares of the Company, as the information is subject to change pending the audit and finalization of full-year results.

Corporate Governance Update

The Board is currently composed of a diverse group of executive, non-executive, and independent non-executive Directors, with Mr. LUO Ningzheng serving as the Chairman, Executive Director, and Chief Executive Officer. The Company remains committed to transparency and will provide further updates as more definitive results become available.

Conclusion

160 Health International Limited’s latest business update reveals a transformative year for the Group, with significant penetration into the public hospital sector through its “160AI Hospital” solution. Investors should closely monitor the Company for further announcements, particularly the audited annual results, as this growth trajectory could have meaningful implications for the Company’s valuation and market performance.

Disclaimer: This article is based on preliminary unaudited information provided by 160 Health International Limited and does not constitute investment advice. The Company’s final audited results may differ from the information presented herein. Investors are strongly encouraged to exercise caution and consult their financial advisors before making investment decisions.

View 160 HEALTH Historical chart here